- Claude Science is Anthropic’s newest flagship product, intended to support scientific research in the same way that Claude Code supports software engineering.
- Claude Science can autonomously carry out meaningful work when given concise, high-level instructions, and it has access to tools that make it particularly useful for research in computational biology and drug development.
- Claude Science is now available to all paid Claude subscribers.
- Anthropic will be using Claude Science to pursue its own research into drugs for rare, neglected diseases.
- Claude Science is a full-featured, standalone product.
- Eric Kauderer-Abrams, Anthropic’s head of life sciences, stated, 'It represents how important this is to our mission that this is right up there with Claude Code and Claude Cowork as the next really significant product that we’re releasing.'
- Claude Science can interface with various tools used in genetics, chemistry, and protein biology, which could assist researchers in drug discovery.
- Alexander Tarashansky demonstrated how Claude Science could autonomously identify new drug candidates for phenylketonuria, a rare genetic disease.
- Anthropic is set to see its first profitable quarter, and new contracts with pharmaceutical companies could help ensure its profitability.
Anthropic's Claude Science is a groundbreaking product aimed at revolutionizing scientific research, akin to its predecessor, Claude Code, which supports software engineering.123456789
The tool is designed to autonomously execute significant tasks when provided with clear, high-level instructions.
It boasts capabilities that make it particularly advantageous for fields such as computational biology and drug development.
Eric Kauderer-Abrams, Anthropic’s head of life sciences, emphasized its importance, stating, “It represents how important this is to our mission that this is right up there with Claude Code and Claude Cowork as the next really significant product that we’re releasing.”
Claude Science can interface with various tools utilized in genetics, chemistry, and protein biology, which are essential for researchers seeking new drug candidates.
Notably, Alexander Tarashansky, who led the development of Claude Science, showcased its ability to autonomously identify new drug candidates for phenylketonuria, a rare genetic disorder.
Anthropic is also leveraging Claude Science for its own research into drugs for rare, neglected diseases.
The product is now available to all paid Claude subscribers, marking a significant step in Anthropic's mission to enhance scientific research capabilities.
As the company anticipates its first profitable quarter, new contracts with pharmaceutical firms could further solidify its financial stability amidst changing market dynamics.
“Claude Science is designed to autonomously assist in scientific research, particularly in computational biology and drug development. It is now available to all paid Claude subscribers.”
MIT Technology Review
